Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 24,003Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 7Calquence

PharmaCompass

01

Brand Name : Calquence

Acalabrutinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Calquence

arrow
Medlab Asia & Asia Health
Not Confirmed

Acalabrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 522

2019 Revenue in Millions : 164

Growth (%) : 218

blank

02

Brand Name : Calquence

Acalabrutinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Calquence

arrow
Medlab Asia & Asia Health
Not Confirmed

Acalabrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 1,238

2020 Revenue in Millions : 522

Growth (%) : 137

blank

03

Brand Name : Calquence

Acalabrutinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Calquence

arrow
Medlab Asia & Asia Health
Not Confirmed

Acalabrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 2,057

2021 Revenue in Millions : 1,238

Growth (%) : 66

blank

04

Brand Name : Calquence

Acalabrutinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Calquence

arrow
Medlab Asia & Asia Health
Not Confirmed

Acalabrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 2,514

2022 Revenue in Millions : 2,057

Growth (%) : 22

blank

05

Brand Name : Calquence

Acalabrutinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Calquence

arrow
Medlab Asia & Asia Health
Not Confirmed

Acalabrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 3

2016 Revenue in Millions : 0

Growth (%) : New Launch

blank

06

Brand Name : Calquence

Acalabrutinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Calquence

arrow
Medlab Asia & Asia Health
Not Confirmed

Acalabrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 62

2017 Revenue in Millions : 3

Growth (%) : 1967%

blank

07

Brand Name : Calquence

Acalabrutinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Calquence

arrow
Medlab Asia & Asia Health
Not Confirmed

Acalabrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 164

2018 Revenue in Millions : 62

Growth (%) : 165

blank